Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine in Primary Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained~* Men and women aged of 18 and 65 years inclusive~* Who are followed at the Calgary MS Clinic~* With Primary Progressive Multiple Sclerosis, according to current diagnostic criteria~* Screening Expanded Disability Status Scale score between 4.0 and 6.5 inclusive.~* Screening timed 25 foot walk (average of two trials) of 5.5 seconds or more.~Exclusion Criteria:~* Patients undergoing treatment with antimalarial drugs, amiodarone, dapsone or digoxin~* Patients with known retinopathy~* Patients whose screening ophthalmological exam shows retinopathy~* Patients whose screening MRI scan shows gadolinium enhancing lesions~* Patients with known renal insufficiency~* Patients with known significant hepatic impairment~* Patients with known porphyria~* Patients with known allergy or other intolerability to HCQ, or to gadolinium MRI contrast agent~* Patients currently using Fampridine or 4-aminopyridine~* Patients planning to start Fampridine or 4-aminopyridine during the study period~* Patients planning to start Baclofen or Tizanidine during the duration of the study~* Patients who increase the dose of Baclofen or Tizanidine during the study period~* Patients who receive treatment with Botulinum toxin in the leg muscles during the study period~* Patients using amiodarone, dapsone, digoxin or antimalarial drugs other than HCQ~* Patients who are unable or unwilling to undergo gadolinium enhanced MRI scans~* Pregnant or breast-feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Oral Hydroxychloroquine, 200mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).